SALIX PHARMACEUTICALS, LTD.

Salix Pharmaceuticals, Ltd. specializes in reconstructive materials used in medical procedures. Their primary focus is on anal tissue reconstructive materials (e.g., Solesta®) and urinary tract reconstructive materials derived from microbes (e.g., Deflux®). These products are designed to aid tissue repair or reconstruction in specific anatomical areas.

Salix Pharmaceuticals, Ltd. is headquartered in the United States, meaning its devices fall under FDA jurisdiction. Since the company’s products are classified as Class III devices, they are subject to stricter regulatory controls, including premarket approval (PMA) requirements, as these devices pose higher risks and require substantial clinical evidence to demonstrate safety and effectiveness.

Salix Pharmaceuticals, Ltd.’s devices are included in the FDA’s Unique Device Identifier (UDI) database, which is a centralized system for tracking medical devices. Listing in this database ensures traceability and compliance with FDA regulations, allowing healthcare providers and regulators to verify device details such as manufacturer information, model numbers, and lot-specific identifiers.

The Class III classification for Salix Pharmaceuticals’ devices—such as Solesta® and Deflux®—reflects their higher risk to patients when used in reconstructive procedures. Class III devices typically support or sustain life, are implanted, or present a potential unreasonable risk of illness or injury if they fail. Due to this classification, these products require premarket approval (PMA) from the FDA, demonstrating rigorous clinical trials and safety data before commercialization.